In a phase 3 randomized controlled trial comparing secondary cytoreduction plus chemotherapy versus chemotherapy alone in patients with relapsed ovarian cancer, the coprimary endpoint of overall survival was not statistically different, but in a prespecified sensitivity analysis adjusted for patients who underwent crossover surgery following tumor relapse, there was an increase in overall survival.
- Rong Jiang
- Yanling Feng
- Rongyu Zang